TRT(600085)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 reached ¥3,960,683,771.21, representing a 16.72% increase compared to ¥3,393,267,938.15 in the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥404,165,999.83, a 55.81% increase from ¥259,391,422.53 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥398,816,142.03, up 56.54% from ¥254,774,836.52 in the previous year[4] - Basic earnings per share for Q3 2023 increased to ¥0.295, reflecting a growth of 56.08% compared to ¥0.189 in the same quarter last year[5] - Total operating revenue for the first three quarters of 2023 reached ¥13,721,380,016.26, a 25.5% increase from ¥10,900,279,219.19 in the same period of 2022[16] - Net profit for the first three quarters of 2023 was ¥2,173,313,513.02, representing a 48.9% increase compared to ¥1,459,474,526.09 in 2022[18] - Earnings per share for the first three quarters of 2023 was ¥1.014, compared to ¥0.731 in the same period of 2022[19] - The company reported a comprehensive income total of ¥2,255,099,924.18 for the first three quarters of 2023, compared to ¥1,726,203,979.56 in 2022[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥29,512,237,252.72, marking a 9.09% increase from ¥27,044,491,889.50 at the end of the previous year[5] - The total current liabilities increased to ¥7,071,620,719.28 from ¥6,335,606,579.88, which is an increase of approximately 11.6%[13] - Long-term borrowings rose to ¥1,394,229,071.22 from ¥1,221,797,346.84, indicating an increase of about 14.1%[13] - Total liabilities increased to ¥9,594,453,591.08 in 2023 from ¥8,590,423,576.47 in 2022, reflecting a growth of 11.7%[14] - The total assets of the company amounted to CNY 27,044,491,889.50, slightly down from CNY 27,054,123,244.38, indicating a decrease of about 0.04%[24] - Total liabilities amounted to approximately $8.59 billion, with current liabilities at about $6.34 billion and non-current liabilities at approximately $2.25 billion[25] Shareholder Equity - The equity attributable to shareholders at the end of the reporting period was ¥12,801,744,944.19, an increase of 8.39% from ¥11,807,275,548.61 at the end of the previous year[5] - Total equity attributable to shareholders reached ¥12,801,744,944.19, up from ¥11,810,494,423.01 in the previous year, marking an increase of 8.4%[14] - The company's retained earnings stood at approximately $7.26 billion, showing a slight decrease from the previous figure of $7.27 billion[25] - The total equity reached approximately $18.45 billion, with equity attributable to shareholders totaling around $11.81 billion[25] Cash Flow - The company’s cash flow from operating activities for the year-to-date period was ¥2,394,341,996.15, slightly down by 0.78% from ¥2,413,199,678.13 in the previous year[4] - Cash inflow from operating activities totaled CNY 15,053,570,654.07, an increase from CNY 12,474,599,949.97 in the previous year, representing a growth of approximately 20.5%[20] - Cash outflow from operating activities amounted to CNY 12,659,228,657.92, compared to CNY 10,061,400,271.84 in the same period last year, indicating a rise of about 25.9%[20] - Net cash flow from operating activities was CNY 2,394,341,996.15, slightly down from CNY 2,413,199,678.13, reflecting a decrease of approximately 0.8%[20] - Cash inflow from investing activities was CNY 182,867,448.79, significantly higher than CNY 82,444,226.06 in the previous year, marking an increase of about 121.5%[20] - Cash inflow from financing activities totaled CNY 283,435,000.00, a decrease from CNY 1,687,398,511.60 in the previous year, representing a decline of approximately 83.2%[21] - Net cash flow from financing activities was negative at CNY -1,173,842,441.79, compared to CNY -1,081,895,459.34 in the same period last year, indicating a worsening of about 8.5%[21] Market and Operational Insights - The company reported a 25.88% increase in operating revenue for the year-to-date period, driven by increased demand in the pharmaceutical market and enhanced marketing efforts[7] - The company continues to focus on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[10] - Research and development expenses for the first three quarters of 2023 totaled ¥150,404,351.60, an increase from ¥111,745,143.83 in 2022[18]